Citigroup’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.6K Buy
2,049
+1,156
+129% +$9.6K ﹤0.01% 4958
2025
Q4
$9.3K Sell
893
-19,896
-96% -$200K ﹤0.01% 5084
2025
Q3
$187K Buy
20,789
+5,274
+34% +$46.3K ﹤0.01% 4016
2025
Q2
$202K Sell
15,515
-12,641
-45% -$190K ﹤0.01% 4059
2025
Q1
$711K Sell
28,156
-35,439
-56% -$1.05M ﹤0.01% 3481
2024
Q4
$2.19M Buy
63,595
+36,754
+137% +$1.66M ﹤0.01% 2744
2024
Q3
$1.33M Buy
26,841
+2,351
+10% +$120K ﹤0.01% 3027
2024
Q2
$1.47M Buy
24,490
+8,353
+52% +$477K ﹤0.01% 2596
2024
Q1
$832K Buy
16,137
+1,719
+12% +$84.4K ﹤0.01% 3174
2023
Q4
$581K Buy
14,418
+14,356
+23,155% +$421K ﹤0.01% 3293
2023
Q3
$1.73K Sell
62
-20,053
-100% -$598K ﹤0.01% 5002
2023
Q2
$579K Buy
20,115
+20,103
+167,525% +$447K ﹤0.01% 3267
2023
Q1
$200 Sell
12
-127
-91% -$1.79K ﹤0.01% 5256
2022
Q4
$1.76K Sell
139
-172
-55% -$2.09K ﹤0.01% 5280
2022
Q3
$4K Sell
311
-1,018
-77% -$14K ﹤0.01% 5325
2022
Q2
$19K Buy
1,329
+676
+104% +$8.92K ﹤0.01% 5040
2022
Q1
$8K Sell
653
-1,422
-69% -$17.1K ﹤0.01% 5641
2021
Q4
$23K Buy
2,075
+1,127
+119% +$13.5K ﹤0.01% 5349
2021
Q3
$12K Buy
+948
New +$13K ﹤0.01% 5425

Other funds holding RXST

Citigroup's RXST Position: Q1 2026 in Review

Citigroup increased its RxSight (RXST) stake by 129% in Q1 2026, buying an estimated $9.6K and bringing the position to 2,049 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4958.

Citigroup first reported a position in RXST in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.19M in Q4 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • Citigroup held 2,049 shares of RxSight worth $12.6K as of Q1 2026.
  • Citigroup bought 1,156 RxSight shares in Q1 2026, an estimated $9.6K.
  • RxSight made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4958 holding.
  • Citigroup first reported a position in RxSight in Q3 2021 and has held it in 19 quarters since.
  • Citigroup's RxSight position peaked at $2.19M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.